Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma.

Dai Y, Liu L, Zeng T, Zhu YH, Li J, Chen L, Li Y, Yuan YF, Ma S, Guan XY.

Biochem Biophys Res Commun. 2013 Jul 12;436(4):711-8. doi: 10.1016/j.bbrc.2013.06.021. Epub 2013 Jun 17.

PMID:
23791740
2.

Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas.

Kim HE, Kim DG, Lee KJ, Son JG, Song MY, Park YM, Kim JJ, Cho SW, Chi SG, Cheong HS, Shin HD, Lee SW, Lee JK.

PLoS One. 2012;7(8):e43223. doi: 10.1371/journal.pone.0043223. Epub 2012 Aug 13.

3.

Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.

Zhuo YJ, Xi M, Wan YP, Hua W, Liu YL, Wan S, Zhou YL, Luo HW, Wu SL, Zhong WD, Wu CL.

Int J Mol Med. 2015 Apr;35(4):966-72. doi: 10.3892/ijmm.2015.2086. Epub 2015 Jan 30.

PMID:
25647485
4.

CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients.

Chen L, Chan TH, Yuan YF, Hu L, Huang J, Ma S, Wang J, Dong SS, Tang KH, Xie D, Li Y, Guan XY.

J Clin Invest. 2010 Apr;120(4):1178-91. doi: 10.1172/JCI40665. Epub 2010 Mar 24.

5.

ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth.

Li Y, Zhu Z, Zhang S, Yu D, Yu H, Liu L, Cao X, Wang L, Gao H, Zhu M.

PLoS One. 2011 Mar 15;6(3):e17794. doi: 10.1371/journal.pone.0017794.

6.

Suppression of actopaxin impairs hepatocellular carcinoma metastasis through modulation of cell migration and invasion.

Ng L, Tung-Ping Poon R, Yau S, Chow A, Lam C, Li HS, Chung-Cheung Yau T, Law WL, Pang R.

Hepatology. 2013 Aug;58(2):667-79. doi: 10.1002/hep.26396.

PMID:
23504997
7.

Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of MAD1 and has a suppressive role in mitotic checkpoint signalling in hepatocellular carcinoma.

Sze KM, Chu GK, Mak QH, Lee JM, Ng IO.

J Pathol. 2014 May;233(1):51-60. doi: 10.1002/path.4319. Epub 2014 Jan 27.

PMID:
24374861
8.

Clinicopathologic significance and function of S-phase kinase-associated protein 2 overexpression in hepatocellular carcinoma.

Zhang SH, Qian YM, Liu AW, Cai J, Zhao XL, Wei JJ, Zhu MH.

Hum Pathol. 2012 Jul;43(7):1084-93. doi: 10.1016/j.humpath.2011.08.019. Epub 2011 Dec 26.

PMID:
22204716
9.

SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice.

Li Y, Chen L, Chan TH, Liu M, Kong KL, Qiu JL, Li Y, Yuan YF, Guan XY.

Gastroenterology. 2013 Jan;144(1):179-191.e4. doi: 10.1053/j.gastro.2012.09.042. Epub 2012 Sep 25.

PMID:
23022495
10.

ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma.

Kang YH, Ji NY, Lee CI, Lee HG, Kim JW, Yeom YI, Kim DG, Yoon SK, Kim JW, Park PJ, Song EY.

Amino Acids. 2011 Mar;40(3):1003-13. doi: 10.1007/s00726-010-0729-6. Epub 2010 Sep 7.

PMID:
20821239
11.

Overexpression of HOXA1 correlates with poor prognosis in patients with hepatocellular carcinoma.

Zha TZ, Hu BS, Yu HF, Tan YF, Zhang Y, Zhang K.

Tumour Biol. 2012 Dec;33(6):2125-34. doi: 10.1007/s13277-012-0472-6. Epub 2012 Aug 4.

PMID:
22864671
12.

SIN1 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition.

Xu J, Li X, Yang H, Chang R, Kong C, Yang L.

Cancer. 2013 Jun 15;119(12):2247-57. doi: 10.1002/cncr.28023. Epub 2013 Apr 5.

13.

Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis.

Huang Y, Li LZ, Zhang CZ, Yi C, Liu LL, Zhou X, Xie GB, Cai MY, Li Y, Yun JP.

J Transl Med. 2012 May 24;10:106. doi: 10.1186/1479-5876-10-106.

14.

Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.

Wang XQ, Zhu YQ, Lui KS, Cai Q, Lu P, Poon RT.

Clin Cancer Res. 2008 Nov 1;14(21):6813-20. doi: 10.1158/1078-0432.CCR-08-0626.

15.

Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma.

Zhao JJ, Pan K, Li JJ, Chen YB, Chen JG, Lv L, Wang DD, Pan QZ, Chen MS, Xia JC.

PLoS One. 2011;6(10):e26608. doi: 10.1371/journal.pone.0026608. Epub 2011 Oct 19.

16.

Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.

Qi R, An H, Yu Y, Zhang M, Liu S, Xu H, Guo Z, Cheng T, Cao X.

Cancer Res. 2003 Dec 1;63(23):8323-9.

17.

Role of a novel splice variant of mitotic arrest deficient 1 (MAD1), MAD1beta, in mitotic checkpoint control in liver cancer.

Sze KM, Ching YP, Jin DY, Ng IO.

Cancer Res. 2008 Nov 15;68(22):9194-201. doi: 10.1158/0008-5472.CAN-08-2600.

18.

Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial-to-mesenchymal transition.

Chung KY, Cheng IK, Ching AK, Chu JH, Lai PB, Wong N.

Hepatology. 2011 Jul;54(1):307-18. doi: 10.1002/hep.24372.

PMID:
21520196
19.

Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.

Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang PY, Xiong YQ, Zhu XD, Xu HX, Kong LQ, Wu WZ, Wang L, Song TQ, Li Q, Tang ZY.

Gastroenterology. 2012 Dec;143(6):1641-1649.e5. doi: 10.1053/j.gastro.2012.08.032. Epub 2012 Aug 23.

PMID:
22922424
20.

Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis.

Liu B, Zhang J, Huang C, Liu H.

PLoS One. 2012;7(8):e43147. doi: 10.1371/journal.pone.0043147. Epub 2012 Aug 13.

Items per page

Supplemental Content

Write to the Help Desk